Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Licensed providers evaluate your eligibility and create a personalized plan using semaglutide or tirzepatide, with prescriptions sent to your preferred pharmacy
Lifestyle advice Weight loss medication works best when combined with healthy lifestyle habits
Glutathione occurs naturally in our body, acting as the main antioxidant of every single cell in our body
Vitamin D and calcium regulation of epidermal wound healing
The result, says Ihlenfeldt, is that awareness has overtaken evidence